NovoNordisk insulin (human insulin) (various short-, rapid-, intermediate-, mixed- and long-acting forms)

Human medicines European public assessment report (EPAR): Cablivi, caplacizumab, Date of authorisation: 30/08/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Otulfi, ustekinumab, Date of authorisation: 25/09/2024, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Rezdiffra, resmetirom, Date of authorisation: 18/08/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Trumenba, meningococcal group b vaccine (recombinant, adsorbed), Date of authorisation: 24/05/2017, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Imcivree, setmelanotide, Date of authorisation: 16/07/2021, Revision: 15, Status: Authorised

List of European Union reference dates (EURD) and frequency of submission of periodic safety update reports (PSURs)

Human medicines European public assessment report (EPAR): Avonex, interferon beta-1a, Date of authorisation: 13/03/1997, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR): Pomalidomide Zentiva, pomalidomide, Date of authorisation: 24/07/2024, Revision: 2, Status: Authorised